taiba 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xolremdi (mavorixafor) / X4 Pharma, Norgine
NCT03995108 / 2019-001153-10: Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Active, not recruiting
3
31
Europe, US, RoW
Mavorixafor, AMD11070, X4P-001, Placebo
X4 Pharmaceuticals
WHIM Syndrome
12/24
12/24
NCT06056297: A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Recruiting
3
150
Europe, US, RoW
Mavorixafor, X4P-001, Placebo
X4 Pharmaceuticals
Neutropenia
07/26
08/26
X4P-001-MKKA, NCT03005327: A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Completed
2
8
US, RoW
X4P-001, AMD11070
X4 Pharmaceuticals
WHIM Syndrome
06/22
06/22
NCT05103917: A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Enrolling by invitation
1/2
24
RoW
X4P-001, Toripalimab Injection
Abbisko Therapeutics Co, Ltd
Triple Negative Breast Cancer
11/22
05/23
NCT04154488: A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Completed
1/2
32
US
Mavorixafor, X4P-001
X4 Pharmaceuticals
Neutropenia
08/24
08/24
NCT06858696: A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Recruiting
1
48
US
Mavorixafor
X4 Pharmaceuticals
Hepatic Insufficiency
03/26
04/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xolremdi (mavorixafor) / X4 Pharma, Norgine
NCT03995108 / 2019-001153-10: Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Active, not recruiting
3
31
Europe, US, RoW
Mavorixafor, AMD11070, X4P-001, Placebo
X4 Pharmaceuticals
WHIM Syndrome
12/24
12/24
NCT06056297: A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Recruiting
3
150
Europe, US, RoW
Mavorixafor, X4P-001, Placebo
X4 Pharmaceuticals
Neutropenia
07/26
08/26
X4P-001-MKKA, NCT03005327: A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Completed
2
8
US, RoW
X4P-001, AMD11070
X4 Pharmaceuticals
WHIM Syndrome
06/22
06/22
NCT05103917: A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Enrolling by invitation
1/2
24
RoW
X4P-001, Toripalimab Injection
Abbisko Therapeutics Co, Ltd
Triple Negative Breast Cancer
11/22
05/23
NCT04154488: A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Completed
1/2
32
US
Mavorixafor, X4P-001
X4 Pharmaceuticals
Neutropenia
08/24
08/24
NCT06858696: A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Recruiting
1
48
US
Mavorixafor
X4 Pharmaceuticals
Hepatic Insufficiency
03/26
04/26

Download Options